Stock Talk Update on Hecla Mining, Kinross Gold, and ONCY — Is BMS the Dark Horse?

  

Market Talk 

NVDA gave the market another lift, powered by the nonstop AI buildout and its latest round of strong earnings. Tech names jump back into the spotlight fast, but the leadership never stays in one place for long. What does stay steady is the resource story — real demand, real supply pressure, and none of the hype cycles. That’s why names like Hecla and Kinross remain mainstays here, even when the market is busy chasing whatever tech star lit up the headlines this week. Sometimes the best trades are the ones that don’t need headlines at all.

Stock Talk 

Hecla Mining (HL)

Hecla is one of the few solid U.S. silver producers in a market where China is tightening export controls to keep more silver at home for its vast solar-panel manufacturing and expansive military-equipment buildouts. That means less silver coming out of China and more focus on dependable North American supply. With global silver demand rising and supply tightening, Hecla’s position only gets stronger. Add in gold by-product production from its U.S. mines and the Casa Berardi gold mine in Canada, and Hecla remains a mainstay in the Jones view, with breakout potential still to be seen. It appears to be a good stock to hold and possibly accumulate on dips.

Kinross Gold (KGC)

With gold holding near the $4,000 range, Kinross stands out as one of the steadier names in the gold sector. The company keeps costs low, throws off solid cash flow, and continues to reward shareholders with buybacks and dividend increases instead of dilution. Even if gold dips from these levels, KGC’s all-in sustaining costs are low enough that earnings still look solidly positive. Kinross is also taking a smart, lower-risk expansion path by partnering with junior explorers in high-grade potential plays like RGCCF and PUMXF, all operating in safe North American mining regions. As long as gold stays firm — and even if it softens — KGC’s disciplined strategy and strong cost position give it plenty of room to keep delivering.

Speculation Corner — ONCY (and BMS?)

ONCY just shifted gears with the FDA’s alignment on its Phase 3 pancreatic trial. The design is agreed to, and Pelareorep’s cancer-lysing and immune-activating profile is now in front of regulators — a milestone that finally puts real structure behind the PDAC program.

The bigger angle? The checkpoint players. Keytruda has been everywhere, but checkpoints still struggle in cold-tumor settings like pancreatic, ovarian, and several other solid cancers where ALL the checkpoints usually fail. Opdivo (BMS) is in the same situation — results and sales in these tough cancers have been slower than hoped. If Merck drags its feet, BMS is known to move faster when a new drug can make their checkpoint work in places it normally falls flat. Pelareorep is that kind of immune primer — the piece that turns a “cold” tumor into something a checkpoint can actually attack.

And this is where the story gets bigger. When a small biotech holds something that could strengthen multiple big-pharma checkpoint franchises, you’re not just looking at partnership potential — maybe even buyout potential starts creeping in. Big pharma doesn’t like watching competitors gain the upper hand in cancers they’ve been failing to crack for years. ONCY — it’s a company to watch closely. Here at the Jones Report, we use the word maybe on speculation — maybe some.

Ramaco Resources struggles in a coal mindset

Ramaco Resources with it's METC and METCB has been pushed back into the coal bucket by the market, despite the rare-earth potential sitting under the Brook Mine. The stock is acting like a pure coal play and is being priced that way. The rare-earth story hasn’t clicked with investors because Washington hasn’t moved, the defense sector hasn’t leaned in publicly, and investors don’t reward “potential” without partners or independently verified assays that change the narrative. Until that happens, Ramaco trades like a dog and gets valued like one. The long-term rare-earth opportunity may still be real, but for now it sits in the background rather than driving the stock.

Staying Nimble

In a market that swings from AI euphoria to resource strength and back again, keeping some dry powder never hurts. Some weeks it’s tech, some weeks it’s metals — but opportunity tends to show up for those who stay flexible.  When the headlines get louder and the swings get wider, having room to move can matter more than making the perfect call.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________